118 related articles for article (PubMed ID: 10551561)
21. Omacetaxine: the FDA decision.
Berman E
Clin Adv Hematol Oncol; 2011 Jan; 9(1):57-8. PubMed ID: 21326148
[No Abstract] [Full Text] [Related]
22. Weekly paclitaxel may improve locoregional recurrence by decreasing interstitial fluid pressure in operable node-positive breast cancer patients.
Altundag K; Altundag O; Boruban C; Altundag MB; Turen S
Med Hypotheses; 2006; 66(1):211-2. PubMed ID: 15950399
[No Abstract] [Full Text] [Related]
23. [Paclitaxel (Tesu) as a single agent in the treatment of breast cancer].
Jiang Z; Song S; Liu X
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):445-7. PubMed ID: 10920879
[TBL] [Abstract][Full Text] [Related]
24. "Will weekly work"? Seems to be so...
Seidman AD
J Clin Oncol; 2005 Sep; 23(25):5873-4. PubMed ID: 16087954
[No Abstract] [Full Text] [Related]
25. Better prioritization may speed approval of adjuvant therapies in breast cancer.
Tuma RS
J Natl Cancer Inst; 2008 Jun; 100(12):842-4. PubMed ID: 18544735
[No Abstract] [Full Text] [Related]
26. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
27. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer.
Tanaka S; Nohara T; Iwamoto M; Sumiyoshi K; Kimura K; Takahashi Y; Tanigawa N
Cancer Chemother Pharmacol; 2009 Jul; 64(2):341-6. PubMed ID: 19039589
[TBL] [Abstract][Full Text] [Related]
28. Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer.
Lüftner D; Henschke P; Flath B; Akrivakis C; Schnabel S; Prinz B; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2004; 24(2B):895-906. PubMed ID: 15161043
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Rincon M; Broadwater G; Harris L; Crocker A; Weaver D; Dressler L; Berry D; Sutton L; Michaelson R; Messino M; Kirshner J; Fleming G; Winer E; Hudis C; Appel S; Norton L; Muss H;
Breast Cancer Res Treat; 2006 Dec; 100(3):301-8. PubMed ID: 16773437
[TBL] [Abstract][Full Text] [Related]
30. [Weekly Taxol (Paclitaxel) administration in the second-line treatment of breast cancer].
Dank M
Magy Onkol; 2002; 46(2):189-91. PubMed ID: 12202898
[TBL] [Abstract][Full Text] [Related]
31. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
Herceg D; Vrbanec D
Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
[TBL] [Abstract][Full Text] [Related]
32. Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma.
Altundag K; Dede DS; Purnak T
J Clin Pathol; 2007 Aug; 60(8):958. PubMed ID: 17660346
[No Abstract] [Full Text] [Related]
33. Study finds that hormone status may predict chemotherapy's effectiveness on breast cancer.
McBride D
ONS Connect; 2008 Jan; 23(1):25. PubMed ID: 18284079
[No Abstract] [Full Text] [Related]
34. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
35. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
36. In response to Dr. Formenti et al. (Int J Radiat Oncol Biol Phys 2005, 63:1275-1276).
Kao J; Conzen S; Fleming G; Recant W; Heimann R
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):658. PubMed ID: 16414377
[No Abstract] [Full Text] [Related]
37. Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007.
Altundag K; Bulut N; Dizdar O; Harputluoglu H
Breast Cancer Res Treat; 2006 Dec; 100(3):329-30. PubMed ID: 16897435
[No Abstract] [Full Text] [Related]
38. [Facts and perspectives in the therapy of cancers of the breast, ovary and bronchi].
Internist (Berl); 1999 Aug; 40(8 Suppl Fakten):1-8. PubMed ID: 10511868
[No Abstract] [Full Text] [Related]
39. [Breast carcinoma. Preoperative chemotherapy can preserve the breast].
MMW Fortschr Med; 2002 Oct; 144(42):63. PubMed ID: 12534003
[No Abstract] [Full Text] [Related]
40. Femara approved as first-line breast cancer therapy.
FDA Consum; 2001; 35(3):5. PubMed ID: 11458552
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
